Dyslipidemia in patients with chronic kidney disease: etiology and management.

摘要: Patients with chronic kidney disease (CKD), including those end-stage renal disease, treated dialysis, or transplant recipients have an increased risk for cardiovascular (CVD) morbidity and mortality. Dyslipidemia, often present in this patient population, is important factor CVD development. Specific quantitative qualitative changes are seen at different stages of impairment associated the degree glomerular filtration rate declining. non-dialysis-dependent CKD low high-density lipoproteins (HDL), normal total cholesterol (TC) low-density lipoprotein (LDL) cholesterol, triglycerides as well apolipoprotein B (apoB), lipoprotein(a) (Lp (a)), intermediate- very-low-density (IDL, VLDL; "remnant particles"), small dense LDL particles. In patients nephrotic syndrome lipid profile more atherogenic TC, LDL, triglycerides. Lipid hemodialysis (HD) usually similar to that patients. on peritoneal dialysis (PD) altered dyslipidemia compared HD patients, which nature. These differences may be attributed PD per se but also selection dialytic modality. recipients, VLDL, elevated, whereas HDL significantly reduced. Many factors can influence post-transplant immunosuppressive agents. This population obviously high risk; hence, prompt diagnosis management required improve their clinical outcomes. Various studies shown statins effective reduction mild-to-moderate recipients. However, according recent randomized controlled trials (4D, A Study Evaluate Use Rosuvastatin Subjects Regular Dialysis: Assessment Survival Cardiovascular Events, Heart Renal protection), these beneficial effects uncertain dialyzed Therefore, further research most suitable treatment options needed.